ClinicalTrials.Veeva

Menu

Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Before and After Treatment

Northwestern University logo

Northwestern University

Status

Active, not recruiting

Conditions

Psoriasis

Treatments

Other: Fasting blood draw for lipid assessments

Study type

Observational

Funder types

Other
NIH

Identifiers

NCT03791216
2019-2361

Details and patient eligibility

About

This study will assess differences in inflammatory proteins, lipoprotein composition, cholesterol efflux and HDL-proteome in moderate-to-severe pediatric psoriasis who at baseline begin systemically administered therapy vs: a) healthy controls; and b) patients with milder psoriasis.

Enrollment

62 patients

Sex

All

Ages

6 to 17 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Children ages 6-17 years of all races/ethnicities with plaque and/or extensive guttate psoriasis for at least 6 months and on topical or systemic therapy
  • Patients in the systemic group can be starting a medication for the first time OR transitioning from another systemic if unresponsive and on that previous treatment for ≤ 3 months.
  • Patients may concurrently have psoriatic arthritis if initiation of a systemic medication is warranted by skin severity.
  • Children ages 6-17 years of all races/ethnicities with acne being treated with isotretinoin
  • Children ages 6-17 years of all races/ethnicities without plaque or guttate psoriasis and history of severe acne or treatment with isotretinoin as controls.

Exclusion criteria

  • Patients less than 6 years of age or 18 years and older
  • Patients with congenital heart disease, prior cardiac catheterizations/surgeries, or on cardiac medications in the past two years other than for hypertension (eg, calcium channel-blockers, beta-blockers and vasotropic medications).
  • Patients who have other systemic inflammatory diseases (including atopic dermatitis, severe acne, inflammatory bowel disease, juvenile idiopathic arthritis, connective tissue diseases and/or other autoimmune diseases).
  • Patients who have active infection or malignancy or have suffered from infection requiring oral or parenteral antibiotic in past 2 weeks.
  • Patients and parents/caregivers unable to give written informed consent.

Trial design

62 participants in 4 patient groups

Psoriasis patients to be treated only topically
Treatment:
Other: Fasting blood draw for lipid assessments
Psoriasis patients with moderate-to-severe psoriasis who begin
Treatment:
Other: Fasting blood draw for lipid assessments
Age-, sex- and BMI percentile-matched controls
Treatment:
Other: Fasting blood draw for lipid assessments
Patients being treated with isotretinoin for acne
Treatment:
Other: Fasting blood draw for lipid assessments

Trial contacts and locations

1

Loading...

Central trial contact

DermatologyCTU

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems